Portal vein embolization and its effect on tumour progression for colorectal cancer liver metastases. Issue 10 (24th June 2015)

• Record Type: Journal Article
• Authors: Simoneau, E.; Hassanain, M.; Shaheen, M.; Aljiffry, M.; Molla, N.; Chaudhury, P.; Anil, S.; Khashper, A.; Valenti, D.; Metrakos, P.
• Is Part Of: British journal of surgery. Volume 102:Issue 10(2015:Oct.)
• Page Start: 1240
• Page End: 1249
• Publication Date: 2015-06-24
• Subjects: Surgery -- Periodicals; 617.005
• DOI: 10.1002/bjs.9872
• Languages: English
• ISSNs: 0007-1323

Abstract

<abstract abstract-type="main" id="bjs9872-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="bjs9872-sec-0001" sec-type="section"> <title>Background</title> <p id="bjs9872-para-0001">The aim of this study was to evaluate the long‐term outcomes of patients with colorectal cancer liver metastasis (CRCLM) exhibiting disease progression after portal vein embolization (PVE).</p> </sec> <sec id="bjs9872-sec-0002" sec-type="section"> <title>Methods</title> <p id="bjs9872-para-0002">Patients with CRCLM requiring PVE before hepatectomy between 2003 and 2014 were included. Clinical variables, and liver and tumour volumes determined by three‐dimensional CT volumetry were assessed before and after PVE. Overall and disease‐free survival data were obtained. Univariable and multivariable logistic regression analyses were performed to identify predictors of tumour progression after PVE.</p> </sec> <sec id="bjs9872-sec-0003" sec-type="section"> <title>Results</title> <p id="bjs9872-para-0003">Of 141 patients who underwent PVE, 93 (66·0 per cent) had tumour progression and 17 (12·1 per cent) developed new contralateral lesions. Significantly fewer patients had resectable disease in the group with disease progression than among those with stable disease: 43 (46 per cent) of 93 <italic>versus</italic> 36 (75 per cent) of 48 respectively (<italic>P</italic> = 0·001). Median survival was similar in patients with and without tumour growth after PVE: 22·5 <italic>versus</italic> 26·0 months for patients with unresectable tumours (<italic>P =</italic> 0·706) and 46·2 <italic>versus</italic> 52·2 months for those with resectable disease (<italic>P =</italic> 0·953). However, disease‐free survival for patients with tumour progression after PVE was shorter than that for patients with stable disease (6·0 <italic>versus</italic> 20·2 months; <italic>P =</italic> 0·045). Response to neoadjuvant chemotherapy was the only significant factor associated with tumour progression in multivariable analysis.</p> </sec> <sec id="bjs9872-sec-0004" sec-type="section"> <title>Conclusion</title> <p id="bjs9872-para-0004">Tumour progression after PVE did not affect overall survival, but patients with resected tumours who had tumour growth after embolization experienced earlier recurrence. A borderline response to neoadjuvant chemotherapy seemed to be associated with tumour progression after PVE.</p> </sec> </abstract>